MediMergent Joins CancerX as a Founding Member

MediMergent, a real-world evidence (RWE) company has announced its membership in the CancerX program.

CancerX is a private-public partnership, initiated by the White House as a part of the renewed Cancer Moonshot program. It is a joint initiative by Moffitt Cancer Center, Digital Medicine Society (DiMe), Office for the National Coordinator for Health Information Technology, and the Office of the Assistant Secretary for Health. This collaboration aims to accelerate innovation and breakthroughs in the fight against cancer by bringing together diverse stakeholders to foster greater opportunities and reduce financial burdens associated with cancer care and research.

MediMergent leverages its proprietary technologies in clinical trials, and other patient engagement settings, to demonstrate its impact on health outcomes. Using its suite of serial, interactive, digital surveys, and ML/AI-driven algorithms for advanced analytics, MediMergent supports pharma sponsors, health insurers, and data aggregators in their quest to interrogate big data related to personalized care of cancer patients.

Sandra Garrett, PhD, CEO of MediMergent stated in a press release, "We believe that VOP digital innovations are critical in reshaping the cancer landscape by adding new insights to clinical outcomes and reducing disparities in cancer care delivery among patients. Our relationship with CancerX offers us an unparalleled opportunity to propel digital health practices forward, positively impacting all aspects of the cancer patient's experience."

Ken Borow, MD, chief medical officer of MediMergent discussed the pivotal role of the patient's perspective in the fight against cancer in a press release, "Cancer does not define the patient and treatment must extend well beyond the disease alone. By championing the patient narrative, MediMergent has empowered medical professionals and researchers to gain deeper insights into the unique challenges faced by cancer patients."

"Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we're honored to partner with MediMergent to achieve the ambitious goals of CancerX," said Smit Patel, associate program director at DiMe in a press release. "Through this impressive collaboration, we will establish best practices, build capacity, and demonstrate the impact of innovation on the life of every person on a cancer journey."

Reference

MediMergent Joins CancerX as a Founding Member, Escalating the Voice of the Patient as an Essential Component in the Fight Against Cancer. (2023, August 29). Cision PR Newswire.